(TheNewswire)
Vancouver, B.C. / TheNewswire / March 21, 2018 – MYM
Nutraceuticals Inc. , (CSE: MYM ) (the “Company” or “
MYM ”) announces the granting of 75,000 stock options for Chief Science Officer (CSO), Dr. Charith
Adkar.
Dr. Adkar completed his PhD in Plant Biology and Crop Production from the University of Milano, Italy with the
specialization in Molecular Plant Pathology. He completed his postdoctoral studies at Hirosaki University, Japan and Université de
Sherbrooke, Canada. His areas of expertise include Plant Science, Biotechnology, Microbiology, Molecular host-pathogen interactions
and Bioinformatics. His work has featured in more than 45 scientific publications. He has received several
prestigious fellowships such as: Japan Society for Promotion of Sciences (JSPS), Postdoctoral Fellowships for Foreign
Researchers, Fonds Québécois de la recherche sur la nature et les technologies (FQRNT), Quebec, Canada. He also received the best
research article award from the Phytopathological Society of Japan and Journal of General plant pathology for Research Article of
the Year 2015.
Dr. Adkar will manage MYM’s scientific, research and technological operations. He will work primarily at the
Laval and Weedon production facilities.
“We’re extremely pleased to welcome Dr. Charith Adkar to the MYM team,” said Rob Gietl, CEO of MYM. “Dr. Adkar
will be instrumental in leading MYM to be a global innovator in the science and technology of medicinal cannabis. His proven track
record and research in plant biology and crop production will ensure that MYM will be on the cutting edge of cannabis plant
discovery and research.”
Mr. Adkar will be granted options to purchase 75,000 common shares of the Company in accordance with the
Company's stock option plan. The options are exercisable at a price of $2.88 per share. 25,000 options will vest every six
months from February 23, 2018. Each option will expire one year after its vesting date.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to
produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in
Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production
project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized
medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire
complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany
and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca
Investor Relations
Terry Brown
1.855.696.2261
terry@mymarijuana.ca
Keep up to date with MYM on our social media channels:
Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra
This news release may contain forward-looking statements based on assumptions and judgments of management
regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual
events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention
or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its
business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with
Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities
described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX
Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the
adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the
securities described herein in the United States. The securities described herein have not been registered under the United States
Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the
“United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the
U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is
available.
Copyright (c) 2018 TheNewswire - All rights reserved.